臨床試驗

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

NCT：NCT05403723 · SUSPENDED

NCT IDNCT05403723

狀態SUSPENDED

開始日期2027-01-30

SponsorUniversity of Maryland, Baltimore (OTHER)

First posted2022-06-03

Last updated2026-09-14

簡要摘要

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。